In that study, among 20 heavily pretreated, mostly platinum-resistant, ovarian cancer patients with prior PARP inhibitors (PARPi), four with germinal LoF alterations in BRCA1 and RAD51C genes attained PRs32. This evidence concerns the gene RAD51C and ovarian cancer.